Biotech startups in Geneva, Switzerland
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| FluoSphera | Geneva | Seed | $1.4M | 2026-01-12 |
| iOnctura | Geneva | Series B | $85.7M | 2024-06-20 |
| Neurosterix | Geneva | Series A | $65.0M | 2024-04-03 |
| Adiposs | Geneva | Series A | $5.0M | 2025-06-30 |
| Viroblock | Geneva | Series C | $4.5M | 2012-02-14 |
| PregLem | Geneva | Series B | $32.2M | 2007-12-04 |
6 rows of the CSV in 5 of its 18 columns.
- The 21 biotech startups in Geneva, Switzerland have raised $182.5M in total.
- 3 of them closed their most recent round in the last 12 months, $22.0M combined.
- The largest of those rounds is Planetary's $20.5M Series A, dated April 2026.
- The most recent is Cria Technologies' $124K pre-seed round on 21 June 2026.
- Eclosion SA is an investor in 4 of them, more than any other fund.
- Health care is the most common other sector, with 17 companies (81%).
- 24% were founded in 2020 or later; the median founding year is 2014.
- The most common team size is 1 to 10 employees (57% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
14 of 21| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| FluoSphera | FluoSphera develops drugs. | Biotech | Seed | $1.4M | 2026-01-12 | $3.9M | SOSV, SOSV SF & NY (Fka IndieBio), FONGIT Innovation Fund +2 | 1 to 10 | 2021 |
| Adiposs | Adiposs SA is a clinical-stage life science company developing a first-in-class imaging product for cancer patients. | Biotech | Series A | $5.0M | 2025-06-30 | $7.4M | MassChallenge, Venture Kick, FONGIT Innovation Fund +2 | 1 to 10 | 2020 |
| iOnctura | iOnctura is a clinical-stage biotechnology company developing treatments for cancer. | Biotech | Series B | $85.7M | 2024-06-20 | European Innovation Council, M Ventures, VI Partners +2 | 11 to 50 | 2017 | |
| Neurosterix | Neurosterix is a biopharmaceutical firm creating allosteric modulators for neurological illnesses. | Biotech | Series A | $65.0M | 2024-04-03 | $65.0M | Perceptive Advisors, Xontogeny, Acorn Bioventures | 11 to 50 | 2024 |
| Kejako | Kejako develops a non-invasive solution helping presbyopic patients keep their quality of life. | Biotech | Seed | $789K | 2022-08-01 | MassChallenge, Business Angels Switzerland (BAS), FONGIT | 1 to 10 | 2015 | |
| Chord Therapeutics | Chord Therapeutics is a clinical stage biopharmaceutical company developing drugs for rare diseases. | Biotech | Series A | $16.0M | 2020-10-13 | Omega Funds, Eclosion SA | 1 to 10 | 2014 | |
| MaxiVAX | MaxiVAX is a Swiss clinical-stage biotechnology company. | Biotech | Series B | $5.0M | 2019-11-27 | EIC Accelerator | 1 to 10 | 2005 | |
| Amal Therapeutics | Amal Therapeutics SA is a privately held Swiss and German biotech startup spun off from the University of Geneva. | Biotech | Series B | $32.6M | 2018-11-12 | HTGF (High-Tech Gruenderfonds), Venture Kick, VI Partners +2 | 11 to 50 | 2012 | |
| Andrew Alliance | Andrew Alliance is a Swiss pioneer in robotics for the life sciences sector. | Artificial intelligence | Series C | $14.0M | 2018-06-12 | Venture Kick, Omega Funds, Rancilio Cube Sicaf | 11 to 50 | 2011 | |
| Intelligent Sensory concept | Intelligent Sensory concept is a biotechnology company that specializes in photomodulation. | Biotech | Series A | $2.0M | 2018-05-18 | Rhône Finance | 11 to 50 | 2015 | |
| Endosense | Endosense develops medical technology that improves the reproducibility of catheter ablation for cardiac arrhythmias. | Biotech | Series C | $41.2M | 2013-11-27 | 3i Group, VI Partners, Andera Partners +2 | 51 to 100 | 2003 | |
| Mind-NRG | Mind-NRG develops peptidic neurotrophic factors for psychiatric and neurologic diseases. | Biotech | Series B | $7.9M | 2013-09-04 | Index Ventures, Limburgse Reconversie Maatschappij | 1 to 10 | 2010 | |
| Viroblock | Viroblock is a Swiss company developing antiviral technology for air filtration products. | Biotech | Series C | $4.5M | 2012-02-14 | $4.5M | StartAngels Network, BlueOcean Ventures | 1 to 10 | 2005 |
| PregLem | PregLem is a Swiss biopharmaceutical company that develops and commercializes new drugs. | Biotech | Series B | $32.2M | 2007-12-04 | $58.2M | Sofinnova Partners, Sofinnova Investments, MVM Life Science Partners +1 | 11 to 50 | 2006 |
Table 1. Biotech startups in Geneva, Switzerland: the 14 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 21.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | FluoSphera | FluoSphera develops drugs. | Biotech | Seed | $1.4M | 2026-01-12 | $3.9M | SOSV, SOSV SF & NY (Fka IndieBio), FONGIT Innovation Fund +2 | 1 to 10 | 2021 |
Table 2. Biotech startups in Geneva, Switzerland: the 1 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Eclosion SA | Venture capital firm | Geneva, Switzerland | 4 | 19% | ||
| 2 | FONGIT Innovation Fund | Startup incubator | Geneva, Switzerland | 3 | 14% | 1 | FluoSphera |
| 3 | VI Partners | Venture capital firm | Altendorf, Switzerland | 3 | 14% | ||
| 4 | Venture Kick | Startup incubator | Schlieren, Switzerland | 3 | 14% | ||
| 5 | Omega Funds | Secondary purchaser | Boston, United States | 2 | 10% | ||
| 6 | MassChallenge | Startup accelerator | Boston, United States | 2 | 10% | ||
| 7 | SOSV SF & NY (Fka IndieBio) | Venture capital firm | San Francisco, United States | 1 | 5% | 1 | FluoSphera |
| 8 | SOSV | Venture capital firm | Princeton, United States | 1 | 5% | 1 | FluoSphera |
| 9 | Mountain Labs | Startup incubator | Saanen, Switzerland | 1 | 5% | 1 | FluoSphera |
| 10 | EFI Lake Geneva Ventures | Venture capital firm | Geneva, Switzerland | 1 | 5% | 1 | FluoSphera |
| 11 | Schroders Capital | Private equity firm | London, United Kingdom | 1 | 5% | ||
| 12 | M Ventures | Corporate venture arm | Amsterdam, The Netherlands | 1 | 5% | ||
| 13 | European Innovation Council | Startup accelerator | Brussels, Belgium | 1 | 5% | ||
| 14 | Xontogeny | Startup accelerator | Boston, United States | 1 | 5% | ||
| 15 | Perceptive Advisors | Hedge fund | New York, United States | 1 | 5% |
Table 3. Biotech startups in Geneva, Switzerland: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 17 | 81% | $131.8M |
| Artificial intelligence | 1 | 5% | |
| Hardware | 1 | 5% | |
| Software | 1 | 5% | |
| Fintech | 1 | 5% |
Table 4. Biotech startups in Geneva, Switzerland by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Pre-seed | 1 | 5% | $124K |
| Seed | 6 | 29% | $1.0M |
| Series A | 5 | 24% | $16.0M |
| Series B | 5 | 24% | $32.2M |
| Series C | 4 | 19% | $14.0M |
Table 5. Biotech startups in Geneva, Switzerland by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| June 2026 | 1 | 33% | $124K |
| April 2026 | 1 | 33% | $20.5M |
| January 2026 | 1 | 33% | $1.4M |
Table 6. Biotech startups in Geneva, Switzerland: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 3 | 14% | $22.0M |
| 2025 | 1 | 5% | $5.0M |
| 2024 | 2 | 10% | $150.7M |
| 2022 | 1 | 5% | $789K |
| 2021 | 1 | 5% | $1.0M |
| 2020 | 1 | 5% | $16.0M |
Table 7. Biotech startups in Geneva, Switzerland by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 2 | 10% |
| 2020 to 2022 | 3 | 14% |
| 2015 to 2019 | 4 | 19% |
| 2010 to 2014 | 8 | 38% |
| Before 2010 | 4 | 19% |
Table 8. Biotech startups in Geneva, Switzerland by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 12 | 57% |
| 11 to 50 | 8 | 38% |
| 51 to 100 | 1 | 5% |
Table 9. Biotech startups in Geneva, Switzerland by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Geneva, Switzerland. On 16 November 2026 that is 21 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 14 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 21 rows: 4 have no round amount, 0 no city and 13 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Geneva, Switzerland are on the list?
- 21, in the file dated 16 November 2026. 3 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 21 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.